文献速递膀胱癌与上尿路尿路上皮癌

多学科团队会议对晚期膀胱癌治疗决策的影响

The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer.
PubMed 文献 · BJU Int · 2022-08-05

基于荷兰全国人群癌症登记(BlaZIB研究)中2017年11月至2019年10月诊断的2321例cT2-4aN0/X-1M0尿路上皮癌患者,88.2%在泌尿生殖多学科团队会议(MDTM)中讨论。讨论与接受根治性治疗相关(OR 3.0,95%CI 1.9-4.9),根治性膀胱切除术医院参与亦相关(OR 1.70,95%CI 1.09-2.65),学术中心参与与更高保膀胱治疗率相关(OR 2.05,95%CI 1.31-3.21)。

要点

  • 高龄(>80岁)和较差体力状态(WHO评分1-2 vs 0)与未在MDTM讨论相关(P<0.001)。
  • MDTM讨论与接受根治性治疗相关(OR 3.0,95%CI 1.9-4.9)。
  • 根治性膀胱切除术医院参与与根治性治疗相关(OR 1.70,95%CI 1.09-2.65),学术中心参与与保膀胱治疗相关(OR 2.05,95%CI 1.31-3.21)。

核心结论

  • 对于肌层浸润性膀胱癌患者,MDTM讨论概率与年龄、体力状态及接受根治性治疗相关,尤其当根治性膀胱切除术医院代表参与时。
  • 未来研究应关注MDTM建议对生存数据的影响。

研究设计与样本

  • 全国性、基于人群的荷兰癌症登记(BlaZIB研究),纳入2017年11月至2019年10月诊断的cT2-4aN0/X-1M0尿路上皮细胞癌患者,共2321例。
  • 采用多水平逻辑回归分析MDTM因素与根治性治疗建议及建议遵循情况的关联。

主要发现

  • 2321例患者中2048例(88.2%)在泌尿生殖MDTM中讨论。
  • 高龄(>80岁)和较差WHO体力状态(评分1-2 vs 0)与未讨论相关(P<0.001)。
  • 被讨论与接受根治性治疗相关(OR 3.0,95%CI 1.9-4.9)。
  • 根治性膀胱切除术医院参与与接受根治性治疗相关(OR 1.70,95%CI 1.09-2.65)。
  • 学术中心参与与更高保膀胱治疗率相关(OR 2.05,95%CI 1.31-3.21)。

关键数值与推荐

  • 根治性治疗选项定义为根治性膀胱切除术(伴或不伴新辅助化疗)、放化疗或近距离放疗。
  • MDTM讨论与根治性治疗建议的OR为3.0(95%CI 1.9-4.9)。
  • 根治性膀胱切除术医院参与的OR为1.70(95%CI 1.09-2.65)。
  • 学术中心参与的OR为2.05(95%CI 1.31-3.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来研究应关注MDTM建议对生存数据的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the role of specialised genitourinary multidisciplinary team meetings (MDTMs) in decision-making and identify factors that influence the probability of receiving a treatment plan with curative intent for patients with muscle invasive bladder cancer (MIBC). PATIENTS AND METHODS: Data relating to patients with cT2-4aN0/X-1 M0 urothelial cell carcinoma, diagnosed between November 2017 and October 2019, were selected from the nationwide, population-based Netherlands Cancer Registry ('BlaZIB study'). Curative treatment options were defined as radical cystectomy (RC) with or without neoadjuvant chemotherapy, chemoradiation or brachytherapy. Multilevel logistic regression analyses were used to examine the association between MDTM factors and curative treatment advice and how this advice was followed. RESULTS: Of the 2321 patients, 2048 (88.2%) were discussed in a genitourinary MDTM. Advanced age (>80 years) and poorer World Health Organization performance status (score 1-2 vs 0) were associated with no discussion (P < 0.001). Being discussed was associated with undergoing treatment with curative intent (odds ratio [OR] 3.0, 95% confidence interval [CI] 1.9-4.9), as was the involvement of a RC hospital (OR 1.70, 95% CI 1.09-2.65). Involvement of an academic centre was associated with higher rates of bladder-sparing treatment (OR 2.05, 95% CI 1.31-3.21). Patient preference was the main reason for non-adherence to treatment advice. CONCLUSIONS: For patients with MIBC, the probability of being discussed in a MDTM was associated with age, performance status and receiving treatment with curative intent, especially if a representative of a RC hospital was present. Future studies should focus on the impact of MDTM advice on survival data.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Walraven JEW, Ripping TM, Oddens JR, et al. The influence of multidisciplinary team meetings on treatment decisions in advanced bladder cancer. BJU Int. 2022. PMID: 35861125. doi:10.1111/bju.15856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。